0001104659-23-086626.txt : 20230802 0001104659-23-086626.hdr.sgml : 20230802 20230802092202 ACCESSION NUMBER: 0001104659-23-086626 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230802 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Theriva Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 231133948 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Synthetic Biologics, Inc. DATE OF NAME CHANGE: 20120305 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 8-K 1 tm2322650d1_8k.htm FORM 8-K
0000894158 false 0000894158 2023-08-02 2023-08-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 2, 2023

 

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303

(State or other jurisdiction of

incorporation)

   (Commission File No.)  

(IRS Employer Identification

No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share TOVX NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On August 2, 2023, Theriva Biologics, Inc. (the “Company”) issued a press release announcing that patient dosing has initiated in the U.S. and with four sites open in the U.S. and eight sites open in Spain, the trial remains on track to be fully-enrolled in the first quarter of 2024. Dosing in Spain initiated in January 2023 and the first patients have now received their second doses of intravenous VCN-01, which were well tolerated and demonstrated the expected VCN-01 safety profile .

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

Item 8.01. Other Events. 

 

On August 2, 2023, the Company issued a press release announcing that patient dosing has initiated in the U.S. and with four sites open in the U.S. and eight sites open in Spain, the trial remains on track to be fully-enrolled in the first quarter of 2024. Dosing in Spain initiated in January 2023 and the first patients have now received their second doses of intravenous VCN-01, which were well tolerated and demonstrated the expected VCN-01 safety profile.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)   Exhibits.

 

Exhibit
Number		   Description
99.1   Press Release issued by Theriva Biologics, Inc., dated August 2, 2023
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 2, 2023 THERIVA BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name:  Steven A. Shallcross
    Title: Chief Executive Officer and Chief Financial Officer

  

 

 

 EX-99.1 2 tm2322650d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

 

- Initiated dosing at U.S. sites for VIRAGE -

 

-Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated -

 

-VIRAGE remains on track to complete enrollment in the first quarter of 2024-

 

Rockville, MD, August 2, 2023 – Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced key progress in VIRAGE, a multinational, Phase 2b, randomized, open-label, controlled clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first-line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Patient dosing has initiated in the U.S. and with four sites open in the U.S. and eight sites open in Spain the trial remains on track to be fully-enrolled in the first quarter of 2024. Dosing in Spain initiated in January 2023 and the first patients have now received their second doses of intravenous VCN-01, which were well tolerated with a safety profile consistent with prior clinical trials.

 

VCN-01 is Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus. VCN-01 has been granted Orphan Drug designations from the US Food and Drug Administration and the European Medicines Agency for the treatment of pancreatic cancer.

 

“Initiating dosing in the U.S., and the completion of the second VCN-01 doses for the first patients in Spain, are important accomplishments that add to the strong momentum for VIRAGE, which remains on track to complete enrollment in the first quarter of 2024,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “With a dearth of novel therapies available and a five-year survival rate for metastatic PDAC of only 3%, pancreatic cancer is an indication that is ripe for innovation. Through VIRAGE’s advancement, we aim to demonstrate VCN-01’s ability to address the unmet needs of pancreatic cancer patients by synergistically combining with standard-of-care chemotherapy. We are extremely encouraged by the favorable safety profile following the advancement to the second dose that further differentiates and positions VCN-01 as a leading oncolytic adenovirus. More broadly, this trial will enable us to determine the feasibility of repeated dosing of VCN-01, which could shift the paradigm for standardized treatment cycles that are well established in cancer chemotherapy and immunotherapy, and thereby lead to improved clinical outcomes for patients with PDAC and other solid cancers.”

 

About VIRAGE

 

VIRAGE is a two-arm Phase 2b open-label, randomized, controlled, multicenter clinical trial in patients with histologically confirmed, newly-diagnosed metastatic PDAC. VIRAGE is expected to enroll up to 92 adult participants at up to 25 sites across the US and Spain. In both the control and treatment arms, patients will receive gemcitabine/nab-paclitaxel standard-of-care chemotherapy over 28-day cycles. In the treatment arm only, patients will also receive systemically administered VCN-01 seven-days prior to the first and fourth cycles of gemcitabine/nab-paclitaxel treatment. Primary endpoints for the trial include overall survival and VCN-01 safety/tolerability. Additional endpoints include progression free survival, objective response rate, and measures of biodistribution, VCN-01 replication, and immune response. Since this is an open-label trial, progress will be monitored very closely and steps to accelerate the clinical program may be implemented if supported by the emerging data. More information about the trial is available on Clinicaltrials.gov (NCT05673811), through the Spanish Clinical Trials Registry and European Union Drug Regulating Authorities Clinical Trials Database (EudraCT Number: 2022-000897-24).

 

 

 

 

 

About VCN-01

 

VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 80 patients in Phase 1 and investigator-sponsored clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection).

 

About Theriva™ Biologics, Inc.

 

Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s wholly-owned Spanish subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. In addition to VCN-01, the Company’s clinical-stage candidates include: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.

 

 

 

 

 

Forward-Looking Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding the Virage trial remaining on track to be fully-enrolled in the first quarter of 2024, the  trial enabling the Company to determine the feasibility of repeated dosing of VCN-01, the feasibility of repeated doses shifting the paradigm for standardized treatment cycles that are well established in cancer chemotherapy and immunotherapy, and the trial leading to improved clinical outcomes for patients with PDAC and other solid cancers. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to complete enrollment in the Virage trial when anticipated and anticipated results, the Company’s ability to address the unmet medical needs for treatment of PDAC, the Company’s ability to take advantage of the potential benefits of orphan drug designation, the Company’s ability to reach clinical milestones when anticipated, the Company’s ability to successfully operate the combined US and Spanish business entities , the Company’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

 

For further information, please contact:

 

Investor Relations:

 

Chris Calabrese

 

LifeSci Advisors, LLC

 

ccalabrese@lifesciadvisors.com

 

917-680-5608

 

 

 

 EX-101.SCH 3 syn-20230802.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syn-20230802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syn-20230802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2322650d1_ex99-1img001.jpg GRAPHIC begin 644 tm2322650d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 02, 2023
Entity File Number 001-12584
Entity Registrant Name THERIVA BIOLOGICS, INC.
Entity Central Index Key 0000894158
Entity Tax Identification Number 13-3808303
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9605 Medical Center Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 417-4364
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol TOVX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 tm2322650d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000894158 2023-08-02 2023-08-02 iso4217:USD shares iso4217:USD shares 0000894158 false 8-K 2023-08-02 THERIVA BIOLOGICS, INC. NV 001-12584 13-3808303 9605 Medical Center Drive Suite 270 Rockville MD 20850 301 417-4364 false false false false Common stock, par value $0.001 per share TOVX NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syntheticbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2322650d1_8k.htm syn-20230802.xsd syn-20230802_lab.xml syn-20230802_pre.xml tm2322650d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2322650d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2322650d1_8k.htm" ] }, "labelLink": { "local": [ "syn-20230802_lab.xml" ] }, "presentationLink": { "local": [ "syn-20230802_pre.xml" ] }, "schema": { "local": [ "syn-20230802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "syn", "nsuri": "http://syntheticbiologics.com/20230802", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322650d1_8k.htm", "contextRef": "AsOf2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://syntheticbiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2322650d1_8k.htm", "contextRef": "AsOf2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-086626-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-086626-xbrl.zip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end